Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744698 | 0.81 | BRD4 (0.39) | HTT | |
| SCHEMBL3568177 | 0.78 | HTT (0.38) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL3566940 | 0.77 | HTT (0.38) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL2745502 | 0.76 | HTT (0.36) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL2745359 | 0.75 | KDM4E (0.39) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL2745910 | 0.75 | HTT (0.37) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL2746489 | 0.74 | HTT (0.36) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL3564722 | 0.74 | HTT (0.36) | HTTMAPTCYP2C9KMT2ATK1 | |
| SCHEMBL3567135 | 0.73 | TK2 (0.36) | HTTTK1 | |
| SCHEMBL3567537 | 0.73 | TNKS (0.41) | HTTTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203445-B1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-11-27 | — | — | EP | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| EP-2203445-A1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | Glaxo Group Limited (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009043883-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, DRD5 | HTT 696/4885MAPT 4521/4885CYP2C9 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.